Allogene Therapeutics

IPO

Home - Allogene

Public · South San Francisco, United States · Founded 2018 · $420.0M raised

Employees
51–200
Founded
2018
Business Model
B2B
Total Funding
$420.0M
Last Round
$120.0M Series BApr 2018
Rounds
2
Type
Public

About

Allogene Therapeutics is a clinical-stage biotech pioneering allogeneic CAR T cell therapies — off-the-shelf treatments derived from healthy donor cells — targeting blood cancers and autoimmune diseases. Its pipeline includes ALLO-329 (dual-targeting, FDA IND-cleared 2025) and multiple earlier-generation ALLO-series candidates. The company went public in 2018.

Summary

Allogene Therapeutics is a Biotech company based in South San Francisco, United States, founded in 2018. It has raised $420.0M in total across 2 rounds, most recently a $120.0M Series B round in Apr 2018. Investors include Perceptive Advisors, Pfizer Ventures and TPG (Growth/Rise).

Tech & App Stack

6 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

Post-IPO EquitySecondary MarketApr 2026
$200.4M

Sign up to see all 5 rounds

Series B through Post-IPO Equity — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Allogene Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/allogene-therapeutics"><img src="https://indexed.vc/api/badge/company/allogene-therapeutics" alt="Allogene Therapeutics on Indexed.vc" width="260" height="76" /></a>